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Recurrent HOXB13 mutations in the 
Dutch population do not associate 
with increased breast cancer risk
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The HOXB13 p.G84E mutation has been firmly established as a prostate cancer susceptibility allele. 
Although HOXB13 also plays a role in breast tumor progression, the association of HOXB13 p.G84E with 
breast cancer risk is less evident. Therefore, we comprehensively interrogated the entire HOXB13 coding 
sequence for mutations in 1,250 non-BRCA1/2 familial breast cancer cases and 800 controls. We identified 
two predicted deleterious missense mutations, p.G84E and p.R217C, that were recurrent among breast 
cancer cases and further evaluated their association with breast cancer risk in a larger study. Taken 
together, 4,520 familial non-BRCA1/2 breast cancer cases and 3,127 controls were genotyped including 
the cases and controls of the whole gene screen. The concordance rate for the genotyping assays compared 
with Sanger sequencing was 100%. The prostate cancer risk allele p.G84E was identified in 18 (0.56%) of 
3,187 cases and 16 (0.70%) of 2,300 controls (OR = 0.81, 95% CI = 0.41–1.59, P = 0.54). Additionally, p.R217C 
was identified in 10 (0.31%) of 3,208 cases and 2 (0.087%) of 2,288 controls (OR = 3.57, 95% CI = 0.76–33.57, 
P = 0.14). These results imply that none of the recurrent HOXB13 mutations in the Dutch population are 
associated with breast cancer risk, although it may be worthwhile to evaluate p.R217C in a larger study.
Breast cancer is the second leading cause of cancer death in Western countries and the most frequently diag-
nosed cancer in Western women. A family history of breast cancer is a major risk factor for developing breast 
cancer. Approximately 10–15% of breast cancer patients have at least one first-degree relative with breast cancer. 
Depending on the number of affected first-degree relatives, this implies risk ratios for breast cancer of 1.80 for one 
affected relative to 3.90 for three or more affected relatives1.
Familial breast cancer has been associated with mutations in several high- and moderate-risk breast can-
cer susceptibility genes, as well as an increasing number of low-risk breast cancer susceptibility alleles. The 
two high-risk genes BRCA1 and BRCA2 were identified in the 1990s and germline mutations in these genes 
confer average cumulative lifetime breast cancer risks by age 70 of 65% and 45%, respectively2–4. Mutations 
in moderate-risk genes ATM, CHEK2, PALB2, and RAD50 confer 2- to 4-fold increased breast cancer risks5, 
although recent evidence suggests that the breast cancer risk conferred by PALB2 mutations may be higher than 
initially thought6,7. The more than 90 identified common low-risk alleles, on the other hand, display small effect 
sizes (i.e. per allele odds ratios) of up to 1.38. However, taken together in a polygenic risk score (PRS; calculated 
from 77 SNPs) the lifetime risk of breast cancer for women in the highest quantile of this PRS was 17%9. In total, 
these breast cancer susceptibility genes and alleles account for approximately 35% of the familial breast cancer 
risk, which means that the underlying cause of the majority of the familial breast cancer risk thus still remains 
unexplained.
In this respect, the rare variant c.251G > A (p.G84E; rs138213197) in the HOXB13 gene was reported to be 
associated with prostate cancer10. Meta-analyses have estimated the increased prostate cancer risk from this 
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mutation to be 4- to 5-fold and even higher among early onset prostate cancer patients and prostate cancer 
patients with a family history of prostate cancer11–14. Moreover, fine-scale mapping at the HOXB gene cluster at 
17q21–22 had identified a number of highly correlated common SNPs that were associated with prostate cancer 
risk and tagging the rare HOXB13 p.G84E variant. This not only further established the association between 
HOXB13 p.G84E and prostate cancer risk, but also provided evidence that GWAS associations could actually be 
driven by rare variants15. Interestingly, the HOXB13 gene encodes a transcription factor that plays an important 
regulatory role during embryonic development, but also in tumorigenesis. For example, HOXB13 was reported 
to regulate the transcription of androgen receptor (AR) target genes16 and together with HOXA9, HOXB13 is 
the most commonly deregulated gene in solid cancers17. Moreover, HOXB13 was shown to preferentially bind 
a low-risk prostate cancer susceptibility allele located in an AR and FOXA1 binding site (i.e. rs339331), thereby 
enhancing RFX6 expression and promoting metastasis18.
In breast cancer, HOXB13 gene expression is regulated by estrogen in an ER dependent manner19. 
Furthermore, a high HOXB13:IL17BR expression ratio was found to be a prognostic and predictive biomarker 
for ER-positive breast cancer patients20,21. The poor response to tamoxifen therapy that is predicted from high 
HOXB13 expression has been shown to be mediated by HOXB13 through the direct suppression of ER, the 
induction of IL6 expression and mTOR pathway activation22. Considering these observations, HOXB13 might 
also be a likely candidate for being a breast cancer susceptibility gene. So far, three studies have investigated this 
hypothesis but obtained contradictory results. In the study by Alanee et al.23, the HOXB13 p.G84E mutation was 
shown to confer an increased breast cancer risk, however, Akbari et al. could not replicate this association in a 
larger study24. Laitinen et al. also found no association with breast cancer risk, but did observe a suggestive asso-
ciation in a particular high-risk subgroup25. Importantly, all three studies only investigated the prostate cancer 
risk-associated variant p.G84E.
In this study, we therefore analyzed the entire coding region of the HOXB13 gene in 1,250 Dutch familial 
breast cancer cases and 800 geographically matched controls to establish whether the p.G84E mutation or other 
mutations in the HOXB13 gene are associated with an increased breast cancer risk.
Results
HOXB13 whole gene screen. We evaluated the entire coding sequence of the HOXB13 gene for germline 
mutations in 1,250 non-BRCA1/2 breast cancer patients and 800 controls from the Rotterdam Breast Cancer Study 
(RBCS) study. Using PCR and Sanger sequencing, we identified a total of eleven different rare variants (Table 1) 
and two more common variants (c.366C > T; p.S122S; rs8556; minor allele frequency (MAF) cases = 0.126; MAF 
controls = 0.138 and c.513T > C; p.S171S; rs9900627; MAF cases = 0.079; MAF controls = 0.091). Seven of the 
eleven rare variants were missense variants and five of these were present either in only one case or one control. 
The other two missense variants (i.e. c.251G > A and c.649C > T) were detected in multiple cases and controls 
(Fig. 1). The c.251G > A (p.G84E) mutation was detected in 4 of 1,215 (0.33%) cases and 6 of 759 (0.79%) con-
trols, whereas the c.649C > T mutation was detected in 6 of 1,206 (0.50%) cases and 1 of 765 (0.13%) controls 
(Table 1). For all identified missense variants the carrier frequency was low, resulting in insufficient power to 
draw meaningful statistical inferences from this sample size. However, it did appear that the prostate cancer risk 
variant p.G84E was less prevalent in breast cancer cases than controls, whereas the prevalence of the p.R217C var-
iant appeared to be higher in breast cancer cases compared with controls. Interestingly, both missense mutations 
were predicted to be deleterious based on three different prediction classification tools: PredictSNP26 (i.e. 87% 
for p.G84E and p.R217C), Meta-SNP27 (i.e. 0.730 for p.G84E and 0.895 for p.R217C) and PON-P228 (i.e. 0.967 for 
p.G84E and 0.974 for p.R217C). Moreover, p.G84E is localized in the MEIS binding domain, whereas p.R217C 
is localized to the homeodomain of HOXB13, further increasing the likelihood that these mutations are patho-
genic10. For these reasons, we decided to further pursue these two variants in a second sample set by expanding 
RBCS (i.e. to all indexes from families counselled between 1994 and 2014 for cases and between 1996 and 2010 
for controls) and by including the Amsterdam Breast Cancer Study (ABCS-F).
Position Nucleotide change Amino acid change Rs number
Carrier allele frequency
Controls Cases
5′ UTR c.1-6G > A 0/759 (0%) 1/1215 (0.08%)
Exon 1 c.251G > A p.G84E rs138213197 6/759 (0.79%) 4/1215 (0.33%)
Exon 1 c.328C > G p.P110A 0/759 (0%) 1/1215 (0.08%)
Exon 1 c.330C > A p.P110P rs33993185 1/759 (0.13%) 0/1215 (0%)
Exon 1 c.332C > T p.A111V 0/759 (0%) 1/1215 (0.08%)
Exon 1 c.569C > T p.P190L 0/759 (0%) 1/1215 (0.08%)
Intron 1 c.601 + 49G > A rs200606700 0/759 (0%) 1/1215 (0.08%)
Exon 2 c.649C > T p.R217C rs139475791 1/765 (0.13%) 6/1206 (0.50%)
Exon 2 c.803G > A p.R268Q 0/765 (0%) 1/1206 (0.08%)
Exon 2 c.832G > T p.V278L rs200997384 1/765 (0.13%) 0/1206 (0%)
3′ UTR c.855 + 28C > A 3/765 (0.39%) 5/1206 (0.41%)
Table 1. Rare variants identified by PCR and Sanger sequencing of the HOXB13 gene.
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Genotyping HOXB13 p.G84E and p.R217C. In order to facilitate fast and accurate screening of the 
p.G84E and p.R217C mutations, two custom-designed Taqman genotyping assays were developed for analyz-
ing all samples from the RBCS and ABCS-F case-control studies. In total, all 4,520 non-BRCA1/2 breast cancer 
patients and 3,127 controls were genotyped. These also included the 1,250 non-BRCA1/2 breast cancer patients 
and 800 controls from the RBCS study that were used in the whole gene screen to evaluate the quality of the 
genotyping assay. The concordance between the results from the custom-designed Taqman genotyping assay and 
Sanger sequencing of these patients was 100%. Interestingly, the p.G84E mutation was identified in 18 (0.56%) 
of 3,187 cases and 16 (0.70%) of 2,300 controls (Table 2). Consistent with the results from the whole gene screen, 
the p.G84E mutation was more prevalent in controls than cases, however, this was not statistically significant 
(OR = 0.81, 95% CI = 0.41–1.59, P = 0.54). The p.R217C mutation was identified in 10 (0.31%) of 3,208 cases 
and 2 (0.087%) of 2,288 controls (Table 2). Consistent with the results of the whole gene screen, the p.R217C 
mutation was more prevalent in cases than in controls, but this difference was not significant (OR = 3.57, 95% 
CI = 0.76–33.57, P = 0.14). These results imply that none of the recurrent HOXB13 mutations in the Dutch pop-
ulation are associated with breast cancer risk.
Discussion
The HOXB13 c.251G > A (p.G84E) mutation has been shown to confer a 4- to 5-fold increased prostate cancer 
risk11–13. In this study, we have explored whether HOXB13 gene mutations are also associated with breast can-
cer risk. Our results show that the prostate cancer risk variant p.G84E is not associated with breast cancer risk. 
Figure 1. Identification of the c.251G > A (p.G84E) and c.649C > T (p.R217C) mutations. The lower 
electropherograms show the c.251C > A (left) and the c.649C > T (right) mutations which are indicated  
with an asterisk as compared with the wild-type sequences in the top panels.
Variant Study
Carrier allele frequency
OR (95% CI) P-valueControls Cases
c.251G > A/p.G84E RBCS 3/356 (0.84%) 9/1,465 (0.61%)
ABCS-F 13/1,944 (0.67%) 9/1,722 (0.52%)
Combined 16/2,300(0.70%) 18/3,187 (0.56%) 0.81 (0.41–1.59) 0.54
c.649C > T/p.R217C RBCS 0/355 (0%) 5/1,473 (0.34%)
ABCS-F 2/1,933 (0.10%) 5/1,735 (0.29%)
Combined 2/2,288 (0.087%) 10/3,208 (0.31%) 3.57 (0.76–33.57) 0.14
Table 2.  Association of HOXB13 p.G84E and p.R217C with breast cancer risk. OR: odds ratio, CI: confidence 
interval.
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Furthermore, another recurrent mutation in the HOXB13 gene (i.e. c.649C > T; p.R217C) was also not associated 
with increased breast cancer risk, although it was more prevalent in cases than controls.
Interestingly, Alanee et al. had previously shown that the HOXB13 p.G84E mutation conferred a moderate to 
high breast cancer risk23. The mutation was found in 6 (0.7%) of 877 familial, mostly Caucasian, non-BRCA1/2 
breast cancer cases, while the frequency in controls was 0.1% (OR = 5.7, 95% CI = 1.0–40.7, P = 0.02). However, 
in a larger study (i.e. 4,037 cases of which 1,082 familial and 2,762 controls) conducted by Akbari et al., no 
association of the p.G84E mutation with breast cancer risk was observed among Canadian and Polish women 
of European origin24. The mutation was identified in 7 (0.17%) of 4,037 cases and 4 (0.14%) of 2,762 controls 
(OR = 1.2, 95% CI = 0.3–4.1, P = 1.0). Also a third study by Laitinen et al. consisting of 986 cases (i.e. of which 
323 familial non-BRCA1/2 and 663 unselected) and 1,449 controls found no overall association between the 
p.G84E mutation and (familial) breast cancer risk among Finnish women25. However, the authors did observe a 
suggestive association in a specific high-risk familial subgroup (i.e. 86 cases from the Pirkanmaa area of Finland; 
OR = 3.2, 95% CI = 0.9–11.9). Here in this study, we also did not observe an increased breast cancer risk associ-
ated with the p.G84E mutation in a relatively large study of 3,270 familial non-BRCA1/2 breast cancer cases and 
2,327 controls (OR = 0.81, 95% CI = 0.41–1.59, P = 0.54). It thus appears that the HOXB13 p.G84E mutation is 
not associated with increased breast cancer risk, although it cannot be excluded that it is associated with a specific 
high–risk subgroup. Considering the low population frequency, much larger studies are needed to determine 
whether the latter is indeed the case.
The whole gene screen for HOXB13 also identified c.649C > T (p.R217C) as a recurrent mutation in the Dutch 
population, which was predicted to be pathogenic. In both the discovery as well as the validation phase of the 
study, the mutation was more prevalent in familial breast cases than controls, but the association with breast 
cancer risk was not significant. Considering the wide CIs and the very low population frequency, there is a pos-
sibility that the study was underpowered and failed to detect the association. Evaluation of HOXB13 p.R217C 
in a larger study or a population with a higher carrier allele frequency might therefore still be worthwhile to 
pursue. Since the p.G84E variant varies widely among different geographic populations (i.e. highest in North 
and West-Europeans and lowest in non-Europeans)29,30, this may also be the case for p.R217C. Interestingly, the 
p.R217C mutation had been described before among a few prostate cancer cases29,31, however, Xu et al. reported 
that p.R217C did not co-segregate with prostate cancer in the two families they identified29. Unfortunately, we 
were not able to perform informative segregation analysis in the present study as for only two families we had 
DNA available for two additional family members. In addition, we identified too little carriers of the mutation to 
say anything relevant regarding an excess of prostate cancer in their families as compared with non-carrier cases.
To conclude, none of the recurrent HOXB13 mutations that we identified in the Dutch population were associ-
ated with breast cancer risk, although it may be worthwhile to evaluate p.R217C in a larger study or a population 
with a higher allele frequency.
Methods
Study population. The samples included in this study were from two Dutch breast cancer case-control stud-
ies: RBCS and ABCS-F. RBCS cases (N = 2,751) were selected from the database of the Clinical Genetics Centre 
at Erasmus University Medical Centre in Rotterdam, representing the Southwestern part of the Netherlands. 
Selected families included all families counselled between 1994 and 2014 that presented with at least two cases 
of female breast cancer or at least one case of female breast cancer and one case of ovarian cancer in first- or sec-
ond-degree relatives. At least one of these two cases needed to be diagnosed before the age of 60. For each family, 
the youngest breast cancer patient who had been tested for BRCA1 and BRCA2 was assigned to be the index case 
and included in RBCS. Additionally, breast cancer cases were included that were diagnosed either before 40 years 
with unilateral breast cancer or before 50 years with bilateral breast cancer without having a first or second degree 
relative diagnosed with either breast or ovarian cancer. All cases and their tested relatives were negative for both 
BRCA1 and BRCA2 mutations. Median age of the RBCS cases was 44 years (range 18–92 years). The RBCS control 
population (N = 1,159) was geographically matched and included women from cystic fibrosis families who were 
either spouses of individuals at risk of being carrier of a CFTR mutation or individuals who were tested negative 
for a CFTR mutation and were counselled between 1996 and 2010. Median age of the RBCS controls was 41 years 
(range 10–97 years).
ABCS-F cases (N = 1,769) were selected from the linked databases of the Division of Diagnostic Oncology and 
the Tumor Registry of the Antoni van Leeuwenhoek hospital in Amsterdam32. We included female breast cancer 
patients of all ages (median age was 42 years (range 14–79 years)), without a pathogenic BRCA1/2 mutation or 
unclassified variant, who were counselled in the Family Cancer Clinic and diagnosed and/or treated with cancer 
in the Antoni van Leeuwenhoek hospital in the period 1995–2012. For each family, only the youngest breast can-
cer patient who had been tested for BRCA1 and BRCA2 was included. ABCS-F controls (N = 1,968) are healthy 
women of all ages (median age was 49 years (range 18–69 years)) from the general population and were recruited 
through the blood bank.
All experiments were performed in accordance with the Code of Conduct of the Federation of Medical 
Scientific Societies in the Netherlands (http://www.fmwv.nl). The RBCS and ABCS-F studies were approved by 
the Medical Ethical Committes of the Erasmus Medical Center Rotterdam and the Netherlands Cancer Institute, 
respectively. All individuals gave written informed consent.
PCR and Sanger sequencing. The entire HOXB13 (RefSeq NM_006361.5) coding region was analyzed for 
sequence variations in 1,250 non-BRCA1/2 familial breast cancer cases and 800 controls from RBCS (i.e. indexes 
from families counselled between 1995 and 2009 for cases and between 1996 and 2006 for controls) using PCR 
and Sanger sequencing. Twenty nanograms of DNA, extracted from peripheral blood, was PCR amplified in a 
final volume of 15 μ l containing 1X GoTaq buffer (Promega, Madison, WI), 1.5 mM MgCl2, 200 μ M dNTPs (GE 
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Healthcare, Waukesha, WI), 1 μ M of each primer and 0.75 U of GoTaq polymerase (Promega) using an ABI2720 
thermal cycler (Thermo Scientific, Waltham, MA). First, the PCR reaction was incubated for 5 minutes at 94 °C, 
followed by 35 cycles of 94 °C for 30 seconds, 58 °C for 1 minute and 72 °C for 1 minute. The PCR reaction ended 
with a final extension at 72 °C for 5 minutes. Removal of dNTPs and primers before sequencing was done by 
ExoSAP-IT PCR Product Cleanup (Affymetrix, Santa Clara, CA). Briefly, 2.5 μ l of PCR product was incubated 
with 0.5 μ l of ExoSAP-IT and 1x GoTaq buffer in a final volume of 12.5 μ l. Incubation took place in an ABI2720 
thermal cycler for 15 minutes at 37 °C. Then enzymes were inactivated at 80 °C for 15 minutes before proceeding 
with Sanger sequencing. The sequencing reaction contained 2 μ l of ExoSAP-it treated PCR product, 1 μ l BigDye 
Terminator v3.1 reaction mix (Thermo Scientific), 1X BigDye Terminator sequencing buffer (Thermo Scientific) 
and 0.16 μ M of sequencing primer in a final volume of 10 μ l and was carried out in an ABI2720 thermal cycler 
according to the following protocol: 1 cycle of 96 °C for 2 minutes and 25 cycles of 96 °C for 30 seconds, 58 °C for 
30 seconds and 72 °C for 2 minutes. Subsequently, the sequencing product was precipitated with absolute etha-
nol and 3M of NaAc, resuspended in 20 μ l of Hi-Di formamide (Thermo Scientific), and ran on an ABI3130XL 
Genetic Analyzer (Thermo Scientific). Sequencing electropherograms were analyzed using Mutation Surveyor 
v3.20 software (Softgenetics, State College, PA). Sanger sequencing was successful for 96.2% of the samples and 
PCR and sequencing primer sequences for the two exons of the HOXB13 gene are available in Supplementary 
Table 1.
Taqman genotyping. Genotyping of the c.251G > A (p.G84E; rs138213197) and c.649C > T (p.R217C; 
rs139475791) mutations in the HOXB13 gene was performed for all 7,647 DNA samples from RBCS and ABCS-F 
using custom-made Taqman genotyping assays (Thermo Scientific) on a Mx3000/3005P qPCR machine (Agilent 
Technologies, Santa Clara, CA). For genotyping p.G84E, 0.5X of Taqman genotyping assay and 0.5X of Taqman 
Genotyping Master Mix (Thermo Scientific) was added to 20 ng of genomic DNA in a final volume of 10 μ l, 
whereas for p.R217C, 1X Taqman genotyping assay and 1X ABsolute qPCR Mix, low ROX (Thermo Scientific) 
was added to 20 ng of genomic DNA in a final volume of 10 μ l. Cycling conditions were: 1 cycle of 10 minutes (for 
Taqman Genotyping Master Mix) or 15 minutes (for ABsolute qPCR Mix, low ROX) at 95 °C and 45 cycles of 15 
seconds at 92 °C and 1 minute at 60 °C. The MxPro qPCR software v4.10 (Agilent) was used to visualize the gen-
otyping results. The call rate of the genotyping assays was 97.9% for p.G84E and 98.1% for p.R217C, respectively, 
and Taqman assay design is specified in Supplementary Table 2. The accuracy of both genotyping assays was 
evaluated by comparing genotypes obtained from the 1,250 RBCS cases and 800 RBCS controls through Taqman 
genotyping with genotypes obtained from Sanger sequencing. For quality control, each 96-well plate included a 
wild-type and a heterozygous sample. Samples that were identified to be positive by either Sanger sequencing or 
in Taqman assays were independently confirmed by Sanger sequencing.
Statistical analyses. The association of both HOXB13 mutations (i.e. p.G84E and p.R217C) with breast 
cancer risk was evaluated by comparing the carrier allele frequency between cases and controls using either a χ 2 
test or a Fisher’s exact test (i.e. when the expected frequency ≤ 5 in any of the groups). Odds ratios and their 95% 
confidence intervals were calculated based on 2 × 2 table analysis of the cases and controls. All statistical tests 
were two-sided and P-values were considered statistically significant when smaller than 0.05.
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